New research in breast cancer is ongoing all around the world …
As part of Breast Cancer Awareness month Purdue University is …
Advertisement
Pfizer says Torisel-Avastin failed in cancer study
No difference in disease progression
Updated: Friday, 10 Aug 2012, 4:37 PM EDT
Published : Friday, 10 Aug 2012, 4:37 PM EDT
NEW YORK (AP) - Pfizer said Friday that its drug Torisel failed to help patients with a form of advanced kidney cancer when combined with Roche's drug Avastin.
The study compared renal cell carcinoma patients taking the Torisel-Avastin combination to those taking Avastin plus another cancer drug.
Patients taking the Pfizer combination did not show slower disease progression than those in the other group. Pfizer said.
Torisel is already approved as a stand-alone treatment for advanced renal cell carcinoma.
Comments WLFI.com is migrating to a more stable commenting system called DISQUS. This system is used by CNN, TIME, FOX News, numerous blogging sites and has over 75 Million registered users. Unfortunately we can't migrate our current user accounts to this new system.
To sign up for a DISQUS account, click the DISQUS button just below and to the right and then click Login.
DISQUS lets you login with several different options, including Facebook, Google, Twitter, Yahoo or OpenID. We expect it to allow more conversation and better moderation. If you have any questions, please feel free to comment below.
Email This
Print This
View Story on a Single PageAdvertisement
Advertisement